What is Theravance Biopharma's investment proceeds?

Theravance Biopharma (TBPH) reported investment proceeds of $96M in Q1 2026.

How has Theravance Biopharma's investment proceeds changed year-over-year?

Theravance Biopharma's investment proceeds increased by 194.5% year-over-year, from $32.6M to $96M.

What is the long-term trend for Theravance Biopharma's investment proceeds?

Over 3 years (2021 to 2025), Theravance Biopharma's investment proceeds has grown at a -20.7% compound annual growth rate (CAGR), from $286.2M to $142.98M.

What does investment proceeds mean?

Cash received from sales, maturities, and redemptions of investment securities across all categories.

Theravance Biopharma TBPH Investment Proceeds

Investment Proceeds at other companies

Zevra Therapeutics, Inc.ZVRA

$93.97M+422%

Royalty PharmaRPRX

$4.32M-65.7%

United TherapeuticsUTHR

$1.31B—

PrecigenPGEN

$55.1M+1,105%

Ultragenyx PharmaceuticalRARE

$88M-35.8%

Mirum Pharmaceuticals, Inc.MIRM

$33.89M+94.4%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+68.7%

Enterprise value$642.72M+38.3%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's investment proceeds?: Theravance Biopharma (TBPH) reported investment proceeds of $96M in Q1 2026.
How has Theravance Biopharma's investment proceeds changed year-over-year?: Theravance Biopharma's investment proceeds increased by 194.5% year-over-year, from $32.6M to $96M.
What is the long-term trend for Theravance Biopharma's investment proceeds?: Over 3 years (2021 to 2025), Theravance Biopharma's investment proceeds has grown at a -20.7% compound annual growth rate (CAGR), from $286.2M to $142.98M.
What does investment proceeds mean?: Cash received from sales, maturities, and redemptions of investment securities across all categories.